Reference
Patel D, et al. Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis. Advances in Therapy : 30 May 2019. Available from: URL: http://dx.doi.org/10.1007/s12325-019-00986-7
Rights and permissions
About this article
Cite this article
Early biologic intervention cost-effective in RA. PharmacoEcon Outcomes News 830, 13 (2019). https://doi.org/10.1007/s40274-019-5964-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5964-9